首页> 外文OA文献 >Hypothesis-driven weight of evidence framework for evaluating data within the US EPA’s Endocrine Disruptor Screening Program

【2h】

Hypothesis-driven weight of evidence framework for evaluating data within the US EPA’s Endocrine Disruptor Screening Program

机译：假设驱动的证据权重框架，用于评估美国EPA的内分泌干扰物筛选计划中的数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Regulatory Toxicology and Pharmacology 61 (2011) 185-191. doi:10.1016/j.yrtph.2011.07.007

机译：监管毒理学和药理学（常规）61（2011）185-191。 doi：10.1016 / j.yrtph.2011.07.007

著录项

作者
Applied Pharmacology & Toxicology, Inc., Gainesville, FL, USA ( host institution ); Borgert, Christopher J.; Mihaich, Ellen M.; Ortego, Lisa S.; Bentley, Karin S.; Holmes, Catherine M.; Levine, Steven L.; Becker, Richard A.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 English
中图分类

相似文献

外文文献
中文文献
专利

1. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program. [J] . Borgert CJ, Mihaich EM, Ortego LS, Regulatory Toxicology and Pharmacology: RTP . 2011,第2期

机译：假设驱动的证据权重框架，用于评估美国EPA的内分泌干扰物筛选计划中的数据。
2. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program. [J] . Borgert CJ, Mihaich EM, Ortego LS, Regulatory Toxicology and Pharmacology: RTP . 2011,第2期

机译：假设驱动的证据框架重量，用于评估美国EPA内分泌干扰筛查计划中的数据。
3. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program. [J] . Borgert CJ, Mihaich EM, Ortego LS, Regulatory Toxicology and Pharmacology: RTP . 2011,第2期

机译：假设驱动的证据框架重量，用于评估美国EPA内分泌干扰筛查计划中的数据。
4. IMPLEMENTING TIER I MAMMALIAN ASSAYS TO MEET DATA REQUIREMENTS FOR THE U.S. EPA ENDOCRINE DISRUPTOR SCREENING PROGRAM (EDSP) [C] . Katherine Coady, Sue Marty Rapra International Conference on Encocrine Disruptors . 2011

机译：实施层I哺乳动物测定以满足美国EPA内分泌干扰筛查计划（EDSP）的数据要求
5. Development and testing of gene expression biomarkers for gonadal dysgenesis in conjunction with the US EPA Endocrine Disruptor Screening Program's Tier 2 Larval Amphibian Growth and Development Assay. [D] . Haselman, Jonathan T. 2014

机译：结合美国EPA内分泌干扰物筛查计划的方法2幼虫两栖动物生长发育测定法，开发和测试用于性腺发育不全的基因表达生物标记。
6. Application of Adverse Outcome Pathways to U.S. EPA’s Endocrine Disruptor Screening Program [O] . Patience Browne, Pamela D. Noyes, Warren M. Casey, 2017

机译：不良结果途径在美国EPA内分泌干扰物筛查计划中的应用
7. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA’s Endocrine Disruptor Screening Program [O] . Applied Pharmacology & Toxicology, Inc., Gainesville, FL, USA ( host institution ), Borgert, Christopher J. ( UF author ), Mihaich, Ellen M. ( author ), 2011

机译：假设驱动的证据权重框架，用于评估美国EPA的内分泌干扰物筛选计划中的数据
8. EPA's Endocrine Disruptor Screening Program Should Establish Management Controls to Ensure More Timely Results. Evaluation Report [R] . Beusse, R., Garduno, H. C., Good, K., 2011

机译：Epa的内分泌干扰物筛查计划应建立管理控制以确保更及时的结果。评估报告

Hypothesis-driven weight of evidence framework for evaluating data within the US EPA’s Endocrine Disruptor Screening Program

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅